Quick Dispatch:
Your tirzepatide cvot trial Tirzepatide vs Dulaglutide for Cardiovascular Outcomes (SURPASS-CVOT) | NEJM orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide cvot trial Tirzepatide vs Dulaglutide for Cardiovascular Outcomes (SURPASS-CVOT) | NEJM ships.
Need Help?
Questions about tirzepatide cvot trial Tirzepatide vs Dulaglutide for Cardiovascular Outcomes (SURPASS-CVOT) | NEJM, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide cvot trial Tirzepatide vs Dulaglutide for Cardiovascular Outcomes (SURPASS-CVOT) | NEJM in your area.
Post hoc analysis of SURPASS-CVOT trial: Tirzepatide was associated with a lower risk of the 6-component cardiorenal endpoint, driven by reduction in all-cause mortality, compared to dulaglutide in patients with T2D and
26.45
Post hoc analysis of SURPASS-CVOT trial: Tirzepatide was associated with a lower risk of the 6-component cardiorenal endpoint, driven by reduction in all-cause mortality, compared to dulaglutide in patients with T2D and
21.36
Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program | Cardiovascular Diabetology
21.29
Tirzepatide for diabetes: on track to SURPASS current therapy
23.88
In patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to major cardiovascular events. , , Read the full SURPASS-CVOT
20.22
01774-X/asset/3608bfb3-6329-4132-95b7-cc3434437493/main.assets/gr2_lrg.jpg)
Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial
20.25
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
28.20
